• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AD
Click for more information
6.90% 2.7¢

ADALTA LIMITED - Corporate Spotlight

Market Cap $14.38M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company... AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
2.7¢ 		Change
-0.002(6.90%) 		Mkt cap ! $14.38M
Open High Low Value Volume
2.8¢ 2.9¢ 2.7¢ $9.445K 348.8K

Buyers (Bids)

No. Vol. Price($)
1 21405 2.8¢
 

Sellers (Offers)

Price($) Vol. No.
2.9¢ 681148 3
View Market Depth
Last trade - 13.13pm 03/05/2024 (20 minute delay) ?
Last
2.7¢ 		  Change
-0.002 ( 3.57 %)
Open High Low Volume
2.7¢ 2.7¢ 2.7¢ 269805
Last updated 13.13pm 03/05/2024 ?
1AD (ASX) Chart

Top Stories

Dancing to that same 70s tune, China, and why I'm backing gold

It is too early to judge what concrete measures the Future Made in Australia policy will entail. However, any policy which has a stated aim to screen qualifying capital for suitability at a government level, does not seem like a strong signal for foreigners to get on a plane, come visit some mine sites and invest.
BPH Energy renews NT Bonaparte Basin permit BPH Energy (ASX:BPH) announced on Friday that it has renewed a key licence in the Northern Territory (NT) overlying the Bonaparte Basin.
Sold out signs go up for RIU Resources Roundup in Sydney More than 115 companies will be participating in this year's RIU Resources Roundup in Sydney.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
Why Princeton Professor rates BlinkLab's autism & ADHD screening app In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.